Neuro-leishmaniasis with cauda equina syndrome and cranial nerve palsy: a rare manifestation of recurrent atypical visceral leishmaniasis.

Neuro-leishmaniasis with cauda equina syndrome and cranial nerve palsy: a rare manifestation of recurrent atypical visceral leishmaniasis.

Publication date: Nov 06, 2024

Visceral leishmaniasis (VL) is a neglected tropical disease primarily affecting Brazil, East Africa, and India, with India accounting for 18% of the global burden. While VL typically presents with systemic symptoms like fever, weight loss, and splenomegaly, it can occasionally manifest atypically, posing significant diagnostic challenges. Neurological presentations of VL are extremely rare, making them difficult to suspect and diagnose. Cases where VL predominantly presents with neurological symptoms are particularly novel, underscoring the need for heightened awareness of such atypical manifestations in endemic regions. A 38-year-old man with history of recurrent atypical VL presented with diffuse lower back pain, progressive tingling, numbness, weakness in the lower extremities, and double vision for one month. Clinical and radiological evaluations suggested cauda equina syndrome and cranial nerve palsy, accompanied by generalized lymphadenopathy, subcutaneous nodules, and skin papules. The differential diagnosis initially included disseminated tuberculosis, histoplasmosis, and lymphoma. Cerebrospinal fluid (CSF) analysis revealed an inflammatory syndrome. Histopathology of lymph node and bone marrow revealed Leishmania amastigotes and subcutaneous nodule and skin biopsy revealed inflammatory cells with granulomas. Furthermore, the qPCR test on DNA from a subcutaneous nodule, lymph node, and CSF was positive for Leishmania kinetoplast DNA. The species was further confirmed as Leishmania donovani through ITS-based PCR amplification and sequencing. Finally, a diagnosis of relapse of VL with lymph node, cutaneous, and neurological involvement, including abducens nerve palsy and cauda equina syndrome, was established. He was treated with combination of liposomal amphotericin B and miltefosine, along with intrathecal hyaluronidase, resulting in significant improvement. Unlike previously reported cases with both systemic and neurological symptoms, our patient predominantly presented with neurological manifestations, making this a unique and novel presentation of VL. This case highlights diagnostic challenges and management of atypical VL, emphasizing neurological involvement and successful therapeutic strategies.

Open Access PDF

Concepts Keywords
Accounting Adult
Lymphadenopathy Amphotericin B
Marrow Amphotericin B
Occasionally Antiprotozoal Agents
Tropical Antiprotozoal Agents
Atypical visceral leishmaniasis
Cauda Equina Syndrome
Cranial Nerve Diseases
Diagnosis, Differential
Humans
Leishmaniasis, Visceral
Male
miltefosine
Miltefosine
Neuro-leishmaniasis
Phosphorylcholine
Phosphorylcholine
Recurrence
Relapse

Semantics

Type Source Name
disease MESH leishmaniasis
pathway KEGG Leishmaniasis
disease MESH cauda equina syndrome
disease MESH cranial nerve palsy
disease MESH visceral leishmaniasis
disease MESH neglected tropical disease
disease MESH weight loss
disease MESH splenomegaly
disease IDO history
disease MESH lower back pain
disease MESH numbness
disease MESH double vision
disease MESH lymphadenopathy
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH histoplasmosis
disease MESH lymphoma
disease MESH syndrome
disease MESH granulomas
disease MESH relapse
disease MESH abducens nerve palsy
drug DRUGBANK Amphotericin B
drug DRUGBANK Miltefosine
drug DRUGBANK Hyaluronidase
disease MESH neurological manifestations
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease MESH palsy
drug DRUGBANK Coenzyme M
disease IDO parasite
disease IDO blood
drug DRUGBANK Iron
drug DRUGBANK Zinc
disease MESH infection
disease MESH hypergammaglobulinemia
drug DRUGBANK Trestolone
disease MESH pancytopenia
disease MESH meningitis
disease MESH pleocytosis
drug DRUGBANK Dextrose unspecified form
disease IDO assay
disease IDO immunodeficiency
disease MESH complications
disease MESH acute renal failure
disease MESH ulcers
disease MESH inflammation
drug DRUGBANK Methyprylon
disease MESH peripheral neuropathy
disease MESH esotropia
drug DRUGBANK Hyaluronic acid
disease MESH foot drop
disease MESH demyelination
disease MESH tremors
disease MESH AIDS
disease MESH malignancy
disease MESH coinfection
disease MESH immunocompromised hosts
disease MESH histiocytosis
disease MESH hyperreflexia
drug DRUGBANK Sodium stibogluconate
disease MESH Fever seizure
disease MESH clinical significance
disease IDO deoxyribonucleic acid
disease MESH mania
drug DRUGBANK L-Aspartic Acid
disease MESH Cutaneous Leishmaniasis
disease MESH Hemophagocytic Lymphohistiocytosis
disease MESH Blood Cancer

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *